Carlyle to buy J&J's diagnostics unit for $4.15B

|About: The Carlyle Group (CG)|By:, SA News Editor

Carlyle (CG) confirms that it has agreed to acquire Johnson & Johnson's (JNJ +0.3%) Ortho-Clinical Diagnostics (OCD) business for $4.15B.

"This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson," J&J CEO Alex Gorsky says.

OCD provides products for screening, diagnosing, monitoring and confirming diseases, including blood-screening equipment and laboratory blood tests. It's a smallish player in a market led by Roche, Siemens and Abbott Labs. (PR)

This was corrected on 01/16/2014 at 08:12 AM. Carlyle's ticker was incorrect.